French biotechnology company Transgene (Euronext Paris:TNG) and ProBioGen, a contract development and manufacturing organisation (CDMO) in biologics, vaccines and viral vectors, announced on Tuesday that they have joined forces to accelerate the development of personalised cancer vaccines.
Through a licence agreement, ProBioGen's high-yielding AGE1.CR.pIX cell line will be integrated into Transgene's myvac platform for large-scale production.
This collaboration leverages ProBioGen's established bioprocessing technology with Transgene's expertise in individualised cancer immunotherapy. The partnership aims to streamline manufacturing processes, ensuring consistent and cost-effective production of patient-specific cancer treatments.
Lunit and Salud Digna partner to advance AI in medical imaging
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Compugen receives new patent covering COM902 use
Natera Ssecures Medicare coverage for Prospera in single lung transplant patients
Oxford Nanopore and UK Biobank partner to create world's largest epigenetic dataset
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Duality Biologics expands collaboration with Adcendo ApS
GSK plc announces US FDA acceptance of review for Blenrep combinations in multiple myeloma